ADMA Biologics Inc ADMA

ADMA Biologics closed at $9.52, down 1.86%, as broad markets were mixed. The drop trailed the Dow's 0.31% loss but outpaced the Nasdaq's near-flat move and the S&P 500's 0.03% decline. In the past month ADMA rose about 0.7% while the Medical sector fell roughly 4.15% and the S&P gained about 0.5%. The company is due to report next quarter with expected earnings of $0.19 per share on $139.8 million in revenue, up about 18.8% and 4.2% year over year, respectively. For the full year, estimates call for $0.78 per share on $536.82 million in revenue, about 30% earnings growth and 5.2% revenue growth. Zacks ranks ADMA #3 (Hold); the stock trades at a forward P/E of 12.49 versus an industry average of 25.2, and the Medical-Biomedical/Genetics group sits in the bottom tier of the sector. Earnings expectations and a cheap forward valuation suggest modest upside, but lack of a clear catalyst keeps risk balanced.

ADMA Biologics reported Q2 2026 earnings call highlights showing Ascentiv surging 24% with gross margin expansion, signaling stronger revenue performance and operational gains. 24% Ascentiv surge and gross margin gains in earnings directly boost revenue outlook and competitive standing.

ADMA Biologics Q2 earnings call covered financial results, revenue growth, operational updates, and outlook for its biopharmaceutical products and pipeline. Q2 earnings details and guidance can moderately influence near-term investor sentiment and valuation.

ADMA Biologics reported second quarter 2026 financial results and issued a business update. Quarterly results and updates supply performance data that can shift near-term investor views without guaranteeing structural change.

ADMA Biologics faces multiple class action lawsuits and regulatory probes over allegations of improper revenue reporting. Class actions and revenue probes create major legal costs, reputational harm and stock volatility that can alter company trajectory.

ADMA Biologics stock plunged 77% over three months, prompting investors to decide whether to hold or sell shares amid the sharp decline. 77% stock plunge over three months signals major challenges that could significantly alter ADMA's trajectory and investor sentiment.

ADMA Biologics faces a federal securities lawsuit alleging revenue inflation through misleading financial reporting. Federal lawsuit over revenue inflation exposes ADMA to major legal costs, regulatory scrutiny, and sharp stock volatility.

ADMA Biologics reset its 2026 guidance and faces BIVIGAM headwinds, leading to valuation reassessment. 2026 guidance reset combined with BIVIGAM headwinds signals major shifts in ADMA financial trajectory and investor outlook.

ADMA Biologics Inc (ADMA) receives FDA label expansion for ASCENIV. FDA label expansion for ASCENIV directly boosts product market reach and revenue outlook for ADMA Biologics.

ADMA Biologics faces ongoing challenges in the IG market, raising questions whether its Asceniv product can provide sufficient support to maintain performance and competitive position. Asceniv discussion points to possible moderate effects on ADMA operations and market stance amid sector pressures.

ADMA Biologics stock plunged 22% over the past month, prompting questions on whether investors should exit positions due to recent sharp underperformance. A 22% monthly plunge can moderately affect near-term investor sentiment and trading dynamics for ADMA without altering long-term fundamentals.

ADMA Biologics faces probes into channel stuffing practices while pursuing pediatric expansion for ASCENIV, creating regulatory risks and growth prospects that directly shape investor sentiment and company trajectory. Channel stuffing probes introduce material regulatory risk while ASCENIV pediatric expansion adds meaningful revenue potential that together can substantially alter ADMA's performance path.

ADMA Biologics' narrative shifts amid tightening targets and intensifying scrutiny. Tightening targets and heightened scrutiny threaten significant shifts in ADMA's strategic trajectory and market performance.

ADMA Biologics Q1 EPS jumped 73% year-over-year despite revenues slipping, with 2026 guidance lowered. Strong EPS growth contrasts with revenue decline and reduced 2026 guidance, likely shifting investor sentiment and future performance trajectory.

ADMA Biologics released Q1 2026 earnings call summary covering quarterly financial results, operational updates, and future outlook. Q1 2026 earnings summary provides key financial metrics and guidance that significantly influence stock price and investor expectations.

ADMA Biologics released Q1 earnings call highlights, detailing financial performance, revenue growth, operational updates, and future guidance for the plasma-derived biologics company. Q1 earnings highlights disclose revenue beats, profitability progress, and production expansions that signal strong growth trajectory and boost investor confidence.

ADMA Biologics Inc released Q1 2026 earnings call transcript detailing financial results, management discussion, and forward guidance. Q1 2026 earnings transcript discloses key financial metrics, operational updates, and guidance that significantly shape investor sentiment and stock trajectory.

ADMA Biologics reported first quarter 2026 financial results and provided a business update. Quarterly earnings reports and business updates directly shape investor sentiment and stock trajectory.

ADMA Biologics' Asceniv label expansion targets primary humoral immunodeficiency in adults and children two years and older, potentially accelerating revenue growth through increased prescriptions and market penetration. Asceniv label expansion opens new patient populations and indications, significantly enhancing ADMA's revenue potential and market position.

Securities investigations target ADMA Biologics (ADMA) following channel stuffing allegations, prompting a critical reassessment of its valuation amid concerns over revenue practices. Securities probes into channel stuffing allegations risk major legal penalties, financial restatements, and eroded investor trust for ADMA Biologics.

ADMA Biologics announces FDA approval to expand ASCENIV label for treating pediatric immune-compromised patients aged two years and older. FDA label expansion to pediatric patients significantly broadens ASCENIV's market access and revenue potential for ADMA.

Canaccord endorses ADMA Biologics while rebutting short-seller claims, positioning these developments as a potential game changer for the company's future. Canaccord's backing and short-seller rebuttal could significantly enhance investor sentiment and alter ADMA's market trajectory.

Canaccord Genuity initiates Buy rating on ADMA Biologics (ADMA), citing improving revenue and margin trends. Analyst Buy initiation highlights improving revenue and margins, likely providing moderate boost to investor sentiment and financial outlook.

Mizuho cuts price target on ADMA Biologics (ADMA) to $24 from $30. Mizuho's price target reduction from $30 to $24 reflects lowered analyst expectations, likely influencing ADMA's market sentiment and short-term stock performance.

Cantor Fitzgerald downgraded ADMA Biologics Inc. (ADMA) to Neutral from Overweight. Analyst downgrade from Overweight to Neutral may moderate investor sentiment and stock performance in the near term.

ADMA Biologics' strong growth in plasma-derived biologics faces short-seller scrutiny over manufacturing issues, plasma supply risks, and high valuation, but robust revenue growth, pipeline expansion, and debt reduction counter the bearish thesis. Short-seller concerns highlight operational risks that could moderately impact market sentiment and financial performance amid ADMA's ongoing growth.

ADMA Biologics (ADMA) stock has outperformed broader market returns, highlighting key facts for investor consideration amid strong performance indicators. Outperforming market returns boosts short-term sentiment and visibility but does not indicate transformative strategic shifts.

ADMA Biologics Inc (ADMA) stock has plunged 42.5% year-to-date, sparking debate on whether now is the ideal time to buy amid potential recovery prospects. ADMA's 42.5% YTD decline highlights financial pressures and market sentiment shifts with moderate potential to influence near-term trajectory.

Cantor Fitzgerald downgraded ADMA Biologics (ADMA) to Neutral from Overweight, citing concerns over execution risks, margin pressures, and valuation after recent gains. Downgrade to Neutral highlights execution risks and valuation concerns, likely causing moderate short-term pressure on stock price and investor sentiment.

ADMA Biologics Inc eyes margin growth and supply expansion in 2026 amid improving operations and production capacity. Margin growth and supply expansion prospects represent major strategic advancements poised to enhance financial performance and competitive positioning by 2026.